Inventor · disambiguated record
Robert J. Desnick
Also filed as: DESNICK ROBERT · DESNICK ROBERT J
28 granted patents·15 pending applications·1,050 citations·filing 1990–2024
98Inventor score
Files withSINAI SCHOOL MEDICINE16ALNYLAM PHARMACEUTICALS INC13ICAHN SCHOOL MED MOUNT SINAI9ALNYIAM PHARMACEUTICALS INC1EDELMANN LISA1
Top patents by PatentIndex Score
43 records- 0199US6583158B1Method for enhancing mutant enzyme activities in lysosomal storage disordersSINAI SCHOOL MEDICINE·Filed 2000·Granted Jun 24, 2003·168 cites·65 claims
- 0296US8349319B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencySINAI SCHOOL MEDICINE·Filed 2010·Granted Jan 8, 2013·32 cites·26 claims
- 0395US9133461B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Sep 15, 2015·19 cites·58 claims
- 0494US5580757ACloning and expression of biologically active α-galactosidase A as a fusion proteinSINAI SCHOOL MEDICINE·Filed 1994·Granted Dec 3, 1996·145 cites·15 claims
- 0592US9655954B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2015·Granted May 23, 2017·8 cites·20 claims
- 0692US5773278AAcid sphingomyelinase geneMOUNT SINAI MEDICAL CENTER·Filed 1991·Granted Jun 30, 1998·47 cites·17 claims
- 0791US8658162B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2012·Granted Feb 25, 2014·10 cites·11 claims
- 0890US9631193B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 25, 2017·8 cites·45 claims
- 0990US8709408B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2012·Granted Apr 29, 2014·9 cites·13 claims
- 1089US7750050B2Chaperone-based therapy for Niemann-Pick diseaseSINAI SCHOOL MEDICINE·Filed 2004·Granted Jul 6, 2010·30 cites·10 claims
- 1189US5401650ACloning and expression of biologically active α-galactosidase ASINAI SCHOOL MEDICINE·Filed 1992·Granted Mar 28, 1995·77 cites·9 claims
- 1289US5356804ACloning and expression of biologically active human α-galactosidase ASINAI SCHOOL MEDICINE·Filed 1990·Granted Oct 18, 1994·137 cites·17 claims
- 1388US9114139B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2014·Granted Aug 25, 2015·6 cites·18 claims
- 1488US2025034566A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1587US10400239B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 3, 2019·3 cites·51 claims
- 1687US2024254486A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1786US11028392B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 8, 2021·1 cites·37 claims
- 1886US5830850AMethods for the treatment of bone resorption disorders, including osteoporosisSINAI SCHOOL MEDICINE·Filed 1996·Granted Nov 3, 1998·81 cites·5 claims
- 1984US10125364B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Nov 13, 2018·2 cites·36 claims
- 2084US6541218B1Acid sphingomyelinase protein and methods of treating type B Niemann-Pick diseaseSINAI SCHOOL MEDICINE·Filed 1998·Granted Apr 1, 2003·52 cites·18 claims
- 2184US5686240AAcid sphingomyelinase gene and diagnosis of Niemann-Pick diseaseSINAI SCHOOL MEDICINE·Filed 1994·Granted Nov 11, 1997·54 cites·36 claims
- 2284US2025122505A1Compositions and methods for inhibiting expression of the alas1 geneALNYIAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2383US10188705B2Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2017·Granted Jan 29, 2019·2 cites·48 claims
- 2481US10119143B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Nov 6, 2018·3 cites·78 claims
- 2580US2022305091A1Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2022·Application pending·0 cites
- 2678US5491075ACloning and expression of biologically active α-N-acetylgalactosaminidaseSINAI SCHOOL MEDICINE·Filed 1994·Granted Feb 13, 1996·54 cites·15 claims
- 2778US2020181614A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2877US2022403382A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2975US5382524ACloning and expression of biologically active α-n-acetylgalactosaminidaseSINAI SCHOOL MEDICINE·Filed 1990·Granted Jan 17, 1995·42 cites·20 claims
- 3075US2021077593A1Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2020·Application pending·0 cites
- 3174US2021087558A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3274US2023026968A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3369US2019218549A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3468US2019151419A1Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiencyICAHN SCHOOL MED MOUNT SINAI·Filed 2018·Application pending·0 cites
- 3563US6455037B1Cells expressing an αgala nucleic acid and methods of xenotransplantationSINAI SCHOOL MEDICINE·Filed 1996·Granted Sep 24, 2002·25 cites·17 claims
- 3660US11279977B2Materials and methods for identifying spinal muscular atrophy carriersICAHN SCHOOL MED MOUNT SINAI·Filed 2018·Granted Mar 22, 2022·0 cites·13 claims
- 3757US5639607AMethod and kits for detecting a polymorphism in δ-aminolevulinate dehydratase gene which is associated with an altered susceptibility to lead poisoningSINAI SCHOOL MEDICINE·Filed 1994·Granted Jun 17, 1997·22 cites·10 claims
- 3856US5840578AMethods for determining susceptibility to lead poisoningSINAI SCHOOL MEDICINE·Filed 1997·Granted Nov 24, 1998·13 cites·9 claims
- 3951US2003153739A1Acid sphingomyelinase gene and diagnosis of Niemann-pick diseaseMOUNT SINAI MEDICAL CT·Filed 2003·Application pending·0 cites
- 4050US9994898B2Materials and methods for identifying spinal muscular atrophy carriersEDELMANN LISA·Filed 2012·Granted Jun 12, 2018·0 cites·8 claims
- 4148US2010077496A1MO-1, A Gene Associated With Morbid ObesityMT SINAI SCHOOL OF MEDICINE·Filed 2008·Application pending·0 cites
- 4243US2013254908A1MO-1, A Gene Associated With Morbid ObesitySINAI SCHOOL MEDICINE·Filed 2012·Application pending·0 cites
- 4337US2003087863A1Methods for diagnosing and treating a disease mediated by decreased MMP-2 functionSINAI SCHOOL MEDICINE·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert J. Desnick files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →